video
What are those weight loss drugs called, again?

Alex Hogan/STAT
On a recent weekday, STAT's Alex Hogan went to the epicenter of biotech: Kendall Square in Cambridge, Mass. When he asked industry workers on their lunch breaks what those blockbuster weight loss drugs are called, most of them said the same thing: Ozempic.
But of course, that's not technically the generic name for GLP-1 medications. In Alex's latest video for his Status Report series, he explores the possibility that Ozempic could someday lose its trademark if the name becomes the generic term for an entire category of product. (See: dumpster, aspirin, thermos.)
"If you're a trademark lawyer, you have this conflicting instinct," law professor Robin Feldman told Alex. You want the name to be on the tip of people's tongues so they buy it without inciting "genericide," as it's called. Watch the video now. It's a fascinating topic, and Feldman provides some great insight, including why genericide is less common in the pharmaceutical space. On top of that, you'll also get to see Alex shred on some (name brand!) Rollerblade inline skates.
first opinion
The wrong name for a huge problem?
In 2021 (when everything I knew about AI chatbots was from Vauhini Vara's brilliant, prescient personal essay in The Believer) Valerie Black was a Ph.D. student researching how people use chatbots for help coping with thoughts of suicide. Black argued then that it wasn't necessarily crazy or unusual for people to do so, and that it highlighted how few outlets there are otherwise to discuss suicidal ideation.
But these days, the language of insanity is exactly how many people describe our society-level problems with chatbots. The bots hallucinate, while people report AI psychosis. That language both sensationalizes and trivializes the actual problem, Black writes in a new First Opinion essay. For example, "the term AI psychosis shifts focus away from misinformation as an addressable issue, implying that the problem is something inherent to AI — or the user's psyche," she writes. Read more on what Black sees as the bait-and-switch strategy of LLM companies navigating these discussions. And in another, related First Opinion essay published today, two researchers and clinicians argue that doctors need to start asking patients about chatbots.
No comments